World Federation of Hemophilia
-
Glenn Pierce, VP Medical, discusses goals and challenges
Glenn Pierce, MD, PhD was elected as VP Medical for the World Federation of Hemophilia (WFH) at the WFH 2018 World Congress this past May...
-
Alert on the use of vials of water for injection (2.5ml, 5ml and 10ml) included in some LFB BIOMEDICAMENTS products
Please note that LFB BIOMEDICAMENTS has issued an alert concerning a defect in the quality appearance of the water for injection (vials 2.5ml, 5ml and...
-
First case of an anti-drug antibody reported in Hemlibra trial
Roche has reported that a young patient in the HAVEN 2 clinical trial for Hemlibra (emicizumab) has developed an anti-drug antibody to Hemlibra resulting in...
-
Update from Roche on Hemlibra (emicizumab)
Update from Roche on Hemlibra (emicizumab), for more information please click here.
-
Update on Shire and Roche/Genentech patent dispute regarding Hemlibra
Update: On March 28, 2018, Chugai Pharmaceuticals, a subsidiary of Roche, announced that a Japanese court ruled that the hemophilia treatment product Hemlibra (emicizumab) does...
-
Important news for the bleeding disorders community
Important news that impacts the global bleeding disorders community was announced today, with Sanofi to acquire Bioverativ. Click here to read the Sanofi press release.
-
WFH closely monitoring Shire and Roche/Genentech patent dispute
The World Federation of Hemophilia has been closely monitoring the developing situation between Shire and Roche/Genentech and their dispute over patent ownership. We will continue...
-
Update: FDA lifts suspension of Fitusiran trial
The United States Food and Drug Administration has agreed to allow Alnylam’s clinical trial of the novel drug Fitusiran to resume. The FDA and Alnylam...
-
-
